Tumour- and treatment-related colostomy rates following mitomycin C or cisplatin chemoradiation with or without maintenance chemotherapy in squamous cell carcinoma of the anus in the ACT II trial

Annals of Oncology

Volumn 25, Issue 8, 2014, Pages 1616-1622

  Glynne Jones, Robert ^a   Kadalayil, L ^b   Meadows, H M ^b   Cunningham, D ^c   Samuel, L ^d   Geh, J I ^e   Lowdell, C ^f   James, R ^g   Beare, S ^b   Begum, R ^b   Ledermann, J A ^b   Sebag Montefiore, D ^h  

^a MOUNT VERNON CANCER CENTRE   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^e QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^f IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^g Kent Cancer Centre   (United Kingdom)

^h UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Anal cancer; Chemoradiation; Colostomy free survival; Loco regional control; Risk factors; Squamous cell carcinoma

Indexed keywords

CISPLATIN; FLUOROURACIL; HEMOGLOBIN; MITOMYCIN;

ADULT; AGE; ANUS SQUAMOUS CELL CARCINOMA; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; COLOSTOMY; COLOSTOMY FREE SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENDER; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; INCIDENCE; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SQUAMOUS CELL CARCINOMA; SURGICAL RISK; ADJUVANT CHEMORADIOTHERAPY; ADVERSE EFFECTS; ANAL CANAL; ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; MIDDLE AGED; MULTICENTER STUDY; NEOPLASMS, SECOND PRIMARY; PATHOLOGY; STATISTICS AND NUMERICAL DATA; TUMOR RECURRENCE; ANUS CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; DRUG EFFICACY; HIGH RISK PATIENT; SEX DIFFERENCE; SQUAMOUS CELL CARCINOMA OF THE ANUS; TREATMENT OUTCOME;

ANAL CANAL; ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY, ADJUVANT; CISPLATIN; COLOSTOMY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY;

EID: 84905166385     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu188     Document Type: Article

References (24)

1. Bilimoria KY, Bentrem DJ, Rock CE et al. Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base. Dis Colon Rectum 2009; 52(4): 624-31.
2. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61(4): 212-36.
3. UKCCCR. Anal Cancer Working Party: Epidermoid Anal Cancer: Results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil and Mitomycin. Lancet 1996; 348: 1049-1054.
4. Bartelink H, Roelofsen F, Eschwege F et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase iii randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 1997; 15: 2040-2049.
5. Flam M, John M, Pajak TF et al. Role of Mitomycin in combination with Fluorouracil and radiotherapy and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized Intergroup Study. J Clin Oncol 1996; 14: 2527-2539.
6. Bentzen AG, Guren MG, Wanderås EH et al. Chemoradiotherapy of anal carcinoma: survival and recurrence in an unselected national cohort. Int J Radiat Oncol Biol Phys 2012; 83(2): e173-80.
7. Ajani JA, Winter KA, Gunderson LL et al. Fluorouracil, mitomycin and radiotherapy vs fluorouracil, cisplatin and radiotherapy for carcinoma of the anal canal: a randomised controlled trial. JAMA 2008; 199: 1914-21.
8. Gunderson LL, Winter KA, Ajani JA et al. Long-term update of U.S.: GI Intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluoruracil/cisplatin. J Clin Oncol 2012; 30: 4344-51.
9. Peiffert D, Tournier-Rangeard L, Gérard JP et al. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 Trial. J Clin Oncol 2012; 30: 1941-8.
10. Glynne-Jones R, Northover JM, Cervantes A, ESMO Guidelines Working Group. Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21(Suppl 5): v87-92.
11. Friberg B, Svensson C, Goldman S, Glimelius B. The Swedish National Care Programme for Anal Carcinoma--implementation and overall results. Acta Oncol 1998; 37(1): 25-32.
12. Allal AS, Sprangers MA, Laurencet F et al. Assessment of long term quality of life in patients with anal cancer treated by radiotherapy with or without chemotherapy. BJC 1999; 80: 1588-1594.
13. Vordermark D, Sailer M, Flentje M et al. Curative intent radiation therapy in anal carcinoma: quality of life and sphincter control. Radiotherapy and Oncology 1999; 52: 239-243.
14. Deniaud-Alexandre E, Touboul E, Tiret E et al. Results of definitive irradiation in a series of 305 epidermoid carcinomas of the anal canal. Int J Radiat Oncol Biol Phys 2003; 56: 1259-1273.
15. James R, Glynne-Jones R, Meadows HM et al. Mitomycin or cisplatin with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2×2 factorial trial. Lancet Oncol 2013; 14: 516-524.
16. Ajani JA, Winter KA, Gunderson LL et al. US Intergroup Anal Carcinoma Trial: tumor diameter predicts for colostomy. J Clin Oncol 2009; 27(7): 1116-21.
17. Glynne-Jones R, Beare S, Begum R et al. Capturing data on colostomy formation in anal cancer. J Clin Oncol 2013; 31(1): 164.
18. Spiessl B, Hermanek P, Scheibe O, Wagner G, (eds). Union Internationale Contre Le Cancer (UICC) TNM-Atlas Illustrated Guide to the TNM/pTNM-Classification of Malignant Tumours, 4th edition. Berlin, Heidelberg: Springer, 1990.
19. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of competing risk. L Am Stat Assoc 1999; 94: 496-509.
20. Sunesen KG, Nørgaard M, Lundby L et al. Cause-specific colostomy rates after radiotherapy for anal cancer: a Danish multicentre cohort study. J Clin Oncol 2011; 29(26): 3535-40.
21. Cooper R, Mason M, Finan P et al. Defunctioning stomas prior to chemoradiation for anal cancer are usually permanent. Colorectal Dis 2012; 14(1): 87-91.
22. Northover J, Glynne-Jones R, Sebag-Montefiore D et al. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer 2010; 102(7): 1123-8.
23. Aggarwal A, Gayadeen S, Robinson D et al. Clinical target volumes in anal cancer: calculating what dose was likely to have been delivered in the UK ACT II trial protocol. Radiother Oncol 2012; 103(3): 341-6.
24. Buettner F, Gulliford SL, Webb S et al. The dose-response of the anal sphincter region-an analysis of data from the MRC RT01 trial. Radiother Oncol 2012; 103 (3): 347-52.